Who are Rosuvastatin plus clopidogrel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Simvastatin plus ticagrelor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosuvastatin-plus-clopidogrel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rosuvastatin plus clopidogrel — Competitive Intelligence Brief

Rosuvastatin plus clopidogrel (Rosuvastatin plus clopidogrel) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin plus antiplatelet agent combination. Area: Cardiovascular.

marketed Statin plus antiplatelet agent combination HMG-CoA reductase; P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Rosuvastatin plus clopidogrel (Rosuvastatin plus clopidogrel) — Federal University of São Paulo. Rosuvastatin reduces cholesterol synthesis while clopidogrel inhibits platelet aggregation, together reducing cardiovascular risk through lipid lowering and antiplatelet effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rosuvastatin plus clopidogrel TARGET	Rosuvastatin plus clopidogrel	Federal University of São Paulo	marketed	Statin plus antiplatelet agent combination	HMG-CoA reductase; P2Y12 receptor
Simvastatin plus ticagrelor	Simvastatin plus ticagrelor	Federal University of São Paulo	marketed	Statin plus P2Y12 receptor antagonist combination	HMG-CoA reductase; P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin plus antiplatelet agent combination class)

Federal University of São Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rosuvastatin plus clopidogrel — Competitive Intelligence Brief. https://druglandscape.com/ci/rosuvastatin-plus-clopidogrel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab